SG175222A1 - Derivatives of n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, preparation thereof, and therapeutic use thereof - Google Patents
Derivatives of n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, preparation thereof, and therapeutic use thereof Download PDFInfo
- Publication number
- SG175222A1 SG175222A1 SG2011075017A SG2011075017A SG175222A1 SG 175222 A1 SG175222 A1 SG 175222A1 SG 2011075017 A SG2011075017 A SG 2011075017A SG 2011075017 A SG2011075017 A SG 2011075017A SG 175222 A1 SG175222 A1 SG 175222A1
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- disorders
- treatment
- hept
- azabicyclo
- Prior art date
Links
- -1 7-aza-bicyclo[2.2.1]hept-1-yl Chemical group 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 12
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 90
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 44
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 32
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 206010000117 Abnormal behaviour Diseases 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 206010033664 Panic attack Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010001584 alcohol abuse Diseases 0.000 claims description 3
- 208000025746 alcohol use disease Diseases 0.000 claims description 3
- 208000029650 alcohol withdrawal Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- 208000024714 major depressive disease Diseases 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000019899 phobic disease Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 230000009329 sexual behaviour Effects 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 238000000034 method Methods 0.000 description 24
- 239000000203 mixture Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 description 4
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 150000003840 hydrochlorides Chemical group 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012943 hotmelt Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229940093956 potassium carbonate Drugs 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- PBIUDEUWYGBHDW-UHFFFAOYSA-N 2-chloro-1-pyridin-3-ylethanone;hydrochloride Chemical compound Cl.ClCC(=O)C1=CC=CN=C1 PBIUDEUWYGBHDW-UHFFFAOYSA-N 0.000 description 1
- AXOAWWUSRZCGKS-UHFFFAOYSA-N 2-chloro-3-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1Cl AXOAWWUSRZCGKS-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000183286 Arapaima gigas Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000919811 Collyria Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000006824 Eschweiler-Clarke methylation reaction Methods 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 150000007945 N-acyl ureas Chemical class 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- RMJLHTRHKFTQIF-UHFFFAOYSA-N [bromo(dimethoxy)methyl]benzene Chemical compound COC(Br)(OC)C1=CC=CC=C1 RMJLHTRHKFTQIF-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000461 neuroepithelial cell Anatomy 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000711 polarimetry Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
DERIVATIVES OF N-[(7-AZABICYCLO[2.2.1JHEPT-1-YL)-ARYL- -METHYL]BENZAMIDE, PREPARATION THEREOF AND THERAPEUTIC USE oo oo oo | ‘THEREOF = - 5. The present invention relates to N-[(7-azabicyclo[2.2.1]hept-1-yl)-aryl- : methyllbenzamide derivatives, to the preparation thereof and fo the therapeutic use thereof in the treatment or prevention of diseases involving Glyt1 glycine transporters.
The compounds of the invention correspond to general formula (I) a
NL oo 0 oo be in which: - R represents a hydrogen atom or a group chosen from the groups {C4-Cg)alkyl and (Cs-Cr)cycloalkyl, optionally substituted with one or more groups chosen, independently of one another, from. halogen atoms and (Cs-Cr)eycloalkyl, (C»-
Casalkenyl, phenyl, (C;-Cg)alkoxy and hydroxyl groups; the phenyl group being optionally substituted with one or more (C;-Ce)alkoxy groups; - Ry represents a phenyl or naphthyl group, optionally substituted with one or more substituents chosen, independently of one another, from halogen atoms and (C,-
GCgalkyl, (C,-Cglalkoxy, halo-(C4-Cglalkyl, hydroxyl, haio-(C,-Cg)alkoxy, (C,-Cg)alkyl- thio, (C1-Cslalkyl-SO and (C-Cg)alkyl-SO, groups; - R; represents one or more substituents chosen from a hydrogen atom, halogen atoms and halo-(C1-Ce)alkyl, (C1-Ce)alkyl, (Ca-Cy)cycloalkyl, (Cs-Cr)cycloalkyl(Cs- :
Czlatkyl, (Cq-Cglalkoxy, (C:-Cglalkyi-thio, (C4-Cglalkyl-SO and (Ci-Cgalkyl-SO, groups: oo inthe form of a base or of an addition salt with an acid. ~The compounds of formula (1). comprise an asymmetric carbon atom. They can therefore. exist in the form of enantiomers. These enantiomers, including racemic =. mixtures, belong to the invention.
“The compounds of formula (I) can exist in the form of bases or of addition salts with oo * acids. Such addition salts belong to the invention, Co :
These salts are advantageously prepared with pharmaceutically acceptable acids, but the salts of other acids that are of use, for example, for purifying or isolating the compounds of formula (1) also belong to the invention.
In the context of the invention: - the expression “C,.C, where t and z can take the values of 1 to 6” is intended to mean a carbon-based chain that can contain from t fo z carbon atoms, for . : oo ‘example the term “C,.Cg” is intended to mean a carbon-based chain that can © contain from 1 to 6 carbon atoms; - the term “alkyl” is intended to mean a linear or branched, saturated aliphatic group; for example, a C-Cg-alkyl group. represents a linear or branched carbon- based chain containing from 1 to 6 carbon atoms, for example a methyl, ethyl, propyl, isopropyt, butyl, isobutyl, ferf-butyl, pentyl or hexyl; - the term “alkylene” is intended to mean a linear or branched, saturated divalent alkyl group; for example, a Cig-alkylene group represents a linear or branched, divalent carbon-based chain containing from 1 to 6 carbon atoms, for example a methylene, ethylene, 1-methylethylene or propylene; - the term “alkoxy” is intended to mean an -O-alkyl group; - the term “hydroxyl” is intended to mean an -OH group; - the term “alkyl-thio” is intended to mean a sulphur atom substituted with an alkyl group; - the term “halogen atom” is intended to mean a fluorine, a chlorine, a bromine or an iodine; - the term "halo-alkyl” is intended to mean an alkyl group in which one or more hydrogen atoms have been substituted with halogen. By way of example, mention may be made of friftuoromethyl, trifiuoroethyl or pentafluoroethyi groups;
EE - the term “halo-alkoxy” is intended to mean an alkoxy group in which one or more hydrogen atoms have been substituted with halogen.
Among the compounds of general formula ([) which are subjects of the invention, a first group of compounds is constituted of the compounds for which:
~~ WO20101119222 ~~ PCT/FR2010/050711 oo 3 ~~ -R represents a hydrogen atom or a (C;-Cg)alkyl or benzyl group; - Riand R; being as defined above.
Among the compounds of general formula (0 which are subjects of the invention, a second group of compounds is constituted by the compounds for which: - Ry represents a phenyl group; = : - Rand R; being as defined above. :
Among the compounds of general formula (I) which are subjects of the invention, a third group of compounds is constituted of the compounds for which: - Ra represents one or more substituents chosen from a hydrogen atom, halogen atoms and halo-{C;-Cg)alkyl or (C4-Ce)alkyl groups; - Rand R4 being as defined above.
Among the compounds of general formula (I) which are subjects of the invention, a fourth group of compounds is constituted of the compounds for which: - R represents a hydrogen atom or a (C-Cg)alkyl or benzyl group; - Ry represents a phenyl group; « Ry represents one or more substituents chosen from a hydrogen atom, halogen atoms and halo-(C4-Cg)alkyl or (C+-Cs)alkyl groups.
Among the compounds of general formula (I) which are subjects of the invention, a fifth group of compounds is constituted of the compounds for which: - R represents a hydrogen atom or a methyl, ethyl or benzyl group; -R; represents a phenyl group; - Rz represents one or more substituents chosen from a hydrogen atom, a chlorine atom and methyl, ethyl or trifluoromethyl groups, in the form of a base or of an addition salt with an acid. .
The combinations of groups one to five as defined above also belong to the invention. }
Among the compounds of general formula (I) which are subjects of the invention, mention may in particular be made of the following compounds:
»N-[(7-azabicyclo[2.2.1]hept-1-yl)phenylméthyi](2-methyl-3- trifluoromethyt)benzamide; oN-[(7-azabicyclo[2.2.1]hept-1 _yl)phenylmethyl}(2,6-dichloro-3- : - trifluoromethyl)benzamide, and the hydrochloride thereof; e(-)-N-[(7-azabicyclo[2.2.1]hept-1-yl)phenyimethyl](2,6-dichloro-3- trifluoromethyl)benzamide, and the hydrochloride thereof; oN-[(7-azabicyclo[2.2.1]hept-1-yl)phenyimethyl](2-chloro-3-trifluoromethyl)benzamide, and the hydrochloride thereof; o2-chioro-N-[(7-ethyl-7-azabicyclo[2.2.1]hept-1-yl)phenylmethyl}(3- trifluoromethyl)benzamide, and the hydrochloride thereof; o(+)-N-[(7-azabicyclo[2.2. 1]hept-1-yl)phenylmethyl](2,6-dichloro-3- : - trifluoromethyl)benzamide, and the hydrochloride thereof; Co #2-chloro-N-[(7-methyl-7-azabicyclo[2.2. 1Thept-1-yl)phenylimethyll-3-trifluoromethyl- benzamide, and the hydrochloride thereof; + eN-[{7-benzyl-7-azabicyclo[2.2.1}hept-1-yl)phenyimethyl]-(2-methyl-3-trifluoro- methyl)benzamide, and the hydrochloride thereof, oN-[(7-benzyl-7-azabicyclo[2.2. 1]hept-1-yl)phenylmethyi](2-chloro-3- trifluoromethyli}benzamide, and the hydrochloride thereof; oN-[(7-azabicyclo[2.2.1]}hept-1-yl)phenylmethyl}{ 2-chioro-3-ethyl)benzamide, and the hydrochloride thereof.
The compounds of the invention exhibit a particular activity as inhibitors of Glyt1 a glycine transporters, in particular an improved activity and improved safety profile.
The compounds of general formula (I) can be prepared by means of a process illustrated by scheme 1 which follows: oo SCHEME 1 SL Co Lo
So
TE" R, 1 (I) oN,
EE Sm
A diamine of general formula (ll), in which R and Ry are as defined above, in particular when R represents a hydrogen atom or a phenylmethyl group, is coupled with an acid that is activated, for example via a mixed anhydride or an acid chloride 5 of general formula (III) in which Y represents a leaving group derived, for example, : from benzofriazole, from acylurea or a halogen atom and R; is as defined above, using the methods known to those skilled in the art,
The compounds of general formula (I) in which R represents a hydrogen atom can also be prepared from compounds of general formula (l} in which R represents: - either a phenylmethyl group, by deprotecting the nitrogen by hydrogenolysis, - or an alkenyl group, preferably allyl group, by deprotecting the nitrogen, for example with a complex of palladium “zero” according to the methods known to those skilled in the art, - or a dimethoxybenzyl group, by deprotecting using oxidation methods known to those skilied in the art. :
The compounds of general formula (I) in which R is other than a hydrogen atom can : also be prepared from compounds of general formula (I) in which R represents a 20 . hydrogen atom, either by alkylation of said compound of general formula (1) with a halide or mesylate of the RX type, in which R is as defined above and X is a - ) ‘mesylate or halogen, in the presence of an inorganic base, for example potassium - carbonate in acetonitrile; or by means of an Eschweiler-Clarke reaction or reductive amination with a suitable aldehyde or a suitable ketone according to the methods known to those skilled in the art; or with a suitable epoxide derivative, according to the methods known to those skilled in the art.
The diamine of general formula (ll) can be prepared by means of the process i. illustrated by scheme 2 for the amine of general formula (lla). and for the amine of © 30 general formula (IIb) which follows: - - oo EE oo
© WO 2010/119222 ~ PCT/FR2010/050711 6
SCHEME 2
ON N RL N pH—DE Hp —_— ——
CO,CH, CN H,N 3 HN R, (IV) (V) (lla) (lib)
According to scheme 2, the ester of formula (IV) is converted to the nitrile of formula (V) by heating at the reflux of xylene in the presence of the previously formed complex of trimethylaluminium and of ammonium chloride, according to a method described in Synthetic Commun., 1982,12 (13), 989-993 and in Tetrahedron Lett. 10. 1979, (51), 4907-4910. The nitrile of formula (V) is then reacted with the lithiated : aromatic compound of general formula (V1), in which R, is as defined above, in an ethereal solvent such as tetrahydrofuran or ether, at low temperature, for example -70°C. An imine is thus obtained, which is reduced with a reducing agent such as sodium borohydride in a. protic solvent such as methanol, so as to give the : © 15 amine of general formula (lla). The amine (la) can be debenzylated by hydrogenation in the presence of a palladium catalyst, so as to give the deprotected amine of general formula (lib).
For the compounds of formulae (IV) and (V), the benzyl group could in particular be replaced with another protective group, for example with an allyl group or a ~~ dimethoxybenzyl group, either: - 5
CL by debenzylating and then reprotecting, for example via an alkylation reaction oo : + with the appropriate electrophilic agent, for example an allyl bromide or a dimethoxybenzyl bromide, according to the methods known to those skilled in the
Co 25 ~ art; oo CL } oo
~ - or according to the method described in Tefrahedron: Asymmetry, 2006 (17), 252-258 by replacing the benzylamine with allylamine or a -dimethoxybenzylamine, in particular 2,4-dimethoxybenzylamine.
Moreover, the chiral compounds of general formula (1) corresponding to the S or R - enantiomers can be obtained by separation of the racemic compounds by chiral- column high performance liquid chromatography (HPLC), or could be obtained by resolving of the racemic amine of general formula (in using a chiral acid, such as dibenzoyltartaric acid, or by fractionated and preferential recrystallization of a diastereoisomeric salt.
The ester of formula (IV) is prepared according to a method described in
Tetrahedron, 2002 (58), 10167-10171.
The nitrile of formula (V) could also be prepared according to a method described in
Tetrahedron: Asymmetry, 2006 (17), 252-258.
The lithiated derivatives of general formula (VI) can be prepared according to - methods known to those skilled in the art.
The acids and acid chlorides of general formula (lll) are commercially available or prepared by analogy with methods known to those skilled in the art.
The examples which foliow illustrate the preparation of some compounds of the invention. In these examples: - the elemental microanalyses, the [IR and NMR spectra and the chiral-column
HPLC confirm the structures and the enantiomeric purities of the compounds obtained, . | EE - ) 25 - For the NMR descriptions, "m" means multiplet, "s" singlet, "t" triplet, "d” doublet, "q" quadruplet, dxd means double doublet, txt means triple triplet, dxt means double triplet, etc., oo - The numbers indicated between parentheses in the titles of the examples - correspond to those of the 1%! column of the table given later, | } - “decomp.” means "decomposition", Co oo
N - The nomenclature used is the nomenclature according to the IUPAC (International Union of Pure and Applied Chemisiry) recommendations.
In the names of the compounds, the dash "-" is part of the word and the dash "_" is only used for the break at the end of a line; it should be deleted in the absence of a break and should not be replaced by a normal dash nor by a space.
Example 1 (Compound No. 4): N-[(7-Azabicyclo[2.2.1]hept-1- yl)phenylmethyl}(2-chloro-3-trifluoromethyl)benzamide hydrochloride (1:1} 1.1. (7-Benzy |-7-azabicyclo[2.2.1 heptane }-1-carbonitrile
In a 250 mi three-necked flask under nitrogen, the complex of trimethylaluminium and of ammonium chloride (approximately 0.67M), hereinafter referred to as complex A, is prepared by placing 1.5 g of dry ammonium chioride (28 mmol) in 30 ml of anhydrous toluene, adding thereto, after cooling, 15 ml of a 2N solution of trimethylaluminium in toluene (30 mmol), and leaving the mixture at ambient temperature until no more gas is given off.
In a 250 ml three-necked flask under nitrogen, fitted with a condenser, 1.27 g of methyl (7-benzyl-7-azabicyclo[2.2.1]heptane)-1-carboxylate (5.18 mmol) are placed in 100 m! of anhydrous xylene. : ml of the complex A (13 mmol) are added dropwise and the mixture is refluxed overnight. : 20 After cooling, the medium is acidified to pH 4-5 with a 1N hydrochloric acid solution and is then extracted successively with ethyl acetate (100ml) and then dichloromethane (100 ml).
The organic phases are dried over sodium sulphate, filtered, combined, and then
Co oo evaporated under reduced pressure. : : : }
The residue is purified by silica gel column chromatography, elution being carried out with a mixture of pefroleum ether and ethyl acetate. 210mg of (7-benzyl-7- azabicycio[2.2.1]heptane)-1-carbonitrile are thus obtained in the form of an oil. eT } 'H NMR (200 MHz,CDCls) 8 ppm 7.5 (m; 5H), 3.75 (s, 2H), 3.40 (m, 1H), 2.25 (m, :
C30 2H), 20(m 4H), 14m 2H). EE 1.2. (7-Benzyl-7-azabicyclof2.2.1lhept-1-yl)phenylmethylamine
In a | 50 mi three-necked flask under argon, 045g of (7-benzyl-7- azabicyclo[2.2.1]heptane)-1-carbonitrile (2.12 mmol) is placed, at -70°C, in 15 ml of anhydrous tetrahydrofuran. 565ml of a 0.75M solution (cyclohexane/ether) of phenyllithium (4.24 mmol) are added dropwise.
The mixture is left at -70°C for two and a half hours and then hydrolysed at -20°C : with 10 mi of water. : : 5 After extraction with ethyl acetate, the organic phase is concentrated under reduced : pressure and the residue is then taken up in 20 ml of methanol. 0.40 g of sodium borohydride (10.6 mmol) is added thereto portionwise. The reaction medium is left to stir overnight at ambient temperature.
After evaporation under reduced pressure, the residue is taken up with 25 mi of ether and 25 ml of water. The medium is acidified with 2 1N hydrochloric acid solution and then extracted. The aqueous phase is basified with aqueous ammonia and then reextracted twice with 50 ml of dichloromethane. The organic phases are combined, dried over sodium sulphate, filtered, and evaporated under reduced pressure. The residue is purified by silica gel column chromatography, elution being carried out with : 15 a mixture of dichloromethane and ammoniacal methanol. 0.5g of (7-benzyl-7- azabicyclo[2.2.1}hept-1-yh)phenylmethylamine is thus obtained in the form of an oil which crystallizes. 'H NMR (400 MHz,CDCls) 8 ppm 7.56 -7.22 {m, 10H), 4.31 (s, 1H), 3.86 (d, J = 13.3
Hz, 1H), 3.37 (d, J = 13.3 Hz, 1H), 3.19 (t, J = 4.5 Hz, 1H), 2.23 (m, 1H), 2.00 (m, 1H), 1.80-1.56 {m, 2H), 1.37 (m, 1H), 1.22 -1.06 (m, 2H), 0.97 (m, 1H).
Mp = 87-88°C 1.3. (7-azabicyclol2.2. 1ihept-1-yhphenyimethylamine oo ~~ In an autoclave, 0.5g of (7-benzyl-7-azabicyclo[2.2.1jhept-1-yl)phenylmethylamine © 25 (1.71 mmol) in solution in 20 ml of ethanol and 3.4 mi of IN hydrochloric acid in the oo presence of a spatula tip of palladium on carbon at 10% are placed under a pressure of 7 atmospheres of hydrogen at 50°C for 6 hours. After the catalyst has been filtered off and the filtrate has been concentrated under reduced pressure, the residue is taken up in 25 ml of dichloromethane and 25 mi of water basified with “30 aqueous ammonia. After extraction, the organic phase is dried over sodium sulphate, - oo : filtered, and evaporated under reduced pressure. 0.28 g of (7-azabicyclo[2.2.1]hept- 1-yh)phenyimethylamine is thus obtained in the form of an oil which solidifies in the cold and which is used as it is in the next stage.
H NMR (400 MHz,CDCl3) 8 ppm 7.36 -7.13 (m, 5H), 4.24 (s, 1H), 3.49 (1, J=48 Hz, 1H), 1.74-1.15 (m, 8H).
Mp = 62-63°C 1.4. N-[(7-azabicyclo]2.2.11hept-1-yl)phenylmethyli{(2-chloro-3-trifluoro- methyhbenzamide hydrochloride (1:1)
In a 25 ml round-bottomed flask, 0.26 g of (2-chloro-3-trifluoromethyl)benzoic acid (1.19 mmol), 0.16g of hydroxybenzotriazole (1.19 mmol) and 0.23g of 1-[3-(dimethylamino )propyl]-3-ethylcarbodiimide hydrochloride (1.19 mmol} are dissolved in 5ml of dichloromethane and the mixture is stirred at ambient temperature for 15 minutes. 0.2 g (1.0 mmol) of (7-azabicyclo[2.2.1}hept-1-yt)phenyl- methylamine in solution in 2 ml of dichloromethane is added and the mixture is stirred at ambient temperature overnight.
The reaction medium is then diluted with 2 ml of dichloromethane and then washed successively with water (3 ml), with 1N sodium hydroxide (3 mi) and with a saturated . 15 solution of sodium chloride (3 mil).
The organic phase is dried over sodium sulphate, filtered, and evaporated under reduced pressure. The residue is purified by silica gel column chromatography, : elution being carried out with a mixture of dichloromethane and ammoniacal methanol. 260 mg of N-[(7-azabicyclo[2.2.1]hept-1-yl)phenylmethyl](2-chloro-3- trifluoromethyl)benzamide are thus obtained, said compound being salified in hydrochloride form by solubilisation of the base in ether, addition of an excess of IN hydrochloric acid in ether and then concentration under reduced pressure. 'H NMR (300 MHz, DMSO-d6) & ppm 9.52 (d, J = 9 Hz, 1H), 9.32 (m, 1H), 8.92 (m, ~~ 1H), 7.96 (m, 2H), 7.65 (m, 1H), 7.55-7.30 (m, 5H), 5.69 (d, J = 9.1 Hz, 1H), 4.07 (m, : : 25 1H), 2.30-0.65 (m, 8H). : oo -
Mp = 146.5-147.5°C. oo
Example 2 {Compound No. 5): 2-Chloro-N-[(7-ethyl-7-azabicyclo[2.2.1]hept-1-
Co yliphenylmethyl](3-trifluoromethyl)benzamide hydrochloride (1:1)
Ina 25 ml round-bottomed flask fitted with a condenser, 95mg of N-A(2-° azabicyclo[2.1.1]hex-1-yl)phenylmethyl]{2-chioro-3-trifluoromethyl)benzamide SE (0.23 mmol) are placed in 2 ml of acetonitrile and 64 mg of potassium carbonate, to which 30 pi of iodoethane (0.36 mmol) are added. The reaction medium is stirred overnight at 45°C and then for 3 hours at 50°C and is then concentrated under reduced pressure. The residue is then diluted with 10 ml of dichloromethane and then washed with water (5 ml). After exiraction, the organic phase is dried over sodium sulphate, filtered, and concentrated under reduced pressure. The residue is purified by silica gel column chromatography, elution being carried out with a mixture of dichloromethane and ammoniacal methanol. 90 mg of 2-chloro-N-[(7-ethyl-7- ~ azabicycio[2.2.1]hept-1-yi)phenylmethyl](3-trifluoromethyl)benzamide are thus : : - obtained, said compound being salified in hydrochloride form by solubilisation of the base in dichloromethane, addition of an excess of 1N hydrochloric acid in ether, and then concentration under reduced pressure. "H NMR (400 MHz,DMSO-d6) & ppm 10.29 (m, 1H), 9.48 (d, J = 9.1 Hz, 1H), 8.12 (m, J = 8 Hz, 1H), 7.94 (m, J = 7.6 Hz, 1H), 7.71-7.31 (m, 6H), 5.68 (d, J = 9.3 Hz, 1H), 4.21 (m, 1H), 3.41-3.03 (m, 2H), 2.39-1.15 (m, 11H).
Mp = 189.5-191.5°C.
Example 3 {Compound No. 7): 2-Chloro-N-[(7-methyl-7-azabicyclo[2.2.11hept-1- yi)phenylmethyl](3-trifluoromethyl}benzamide hydrochloride (1:1)
In a 25ml round-bottomed flask fitted with a condenser, 0.09¢g of N-[(2- azabicyclo[2.1.1]hex-1-yl)phenyimethyl}(2-chloro-3-trifluoromethyl)benzamide ’ (0.22 mmol) and 2 ml of formaldehyde are placed in 2 ml of formic acid. The reaction mixture is heated at 100°C for 72 hours. After cooling, the medium is hydrolysed, basified to pH 9 with aqueous ammonia, and then extracted with dichloromethane.
The organic phase is dried over sodium sulphate, filtered, and evaporated under reduced pressure. 70mg of 2-chloro-N-[(7-ethyl-7-azabicyclo[2.2.11hept-1- yl)phenylmethyl](3-trifluoromethyl)benzamide are thus obtained, said compound being salified in hydrochloride form by solubilisation of the base in dichloromethane, addition of an excess of 1N hydrochloric acid in ether and then concentration under reduced pressure. oo 'H NMR (400 MHz,DMSO-d6) 8 ppm 10.58 (m, 1H); 9.54 (d, J = 9.6 Hz, 1H), 8.26 (m,
J=74 Hz, 1H), 7.97 (m, J = 7.6 Hz, 1H), 7.75-7.33 (m, 7H), 5.71 (d, J = 9.4 Hz, 1H),
C0 4.05(m, 1H), 2.87 (m, 3H), 2.44-1.18 (m, 8H). EE oo
RB - oo Mp = 244-246°C. : ) : BN
The other compounds listed in the table are obtained according to the methods described in Examples 1 to 3 using amines of general formula {lla} or (lib), lithium . compounds of general formula (VI), carboxylic acid derivatives of general formula (I11} or alkylating agents that are appropriate.
Table 1 which follows illustrates the chemical structures of some compounds of the invention.
In the “salts” column, “-" denotes a compound in the form of a base, "HCI" denotes a hydrochloride, the number between parentheses indicating the (acid:base) ratio; in the columns R, Ry and Ry: - “Cl” stands for chlorine, - “CH3” stands for methyl, - “Ph” stands for phenyl, - “Bn” stands for benzyl, - “CF3” stands for trifluoromethyl, - in the column “R;", the number before the substituents indicates the position in general formula (1), - The compounds in the table are in the form of hydrochloride solvated with one or more molecules of water.
Compounds No. 3 and 6 in Table 1 form a pair of enantiomers which are separated by preparative HPLC, using a Chirobiotic® T2 5pm column and a 100/0.1/0.05 methanolftriethylamine/acetic acid mixture as solvent. The absolute stereochemistry was determined by X-ray diffraction.
Table 2 gives the physical properties, melting points and optical rotations of the compounds of Table 1. | Co
In Table 2: - the column [aplaoc gives information on the result of analysis of the optical rotation of the compounds of the table at the wavelength of 589 nM and the temperature of "20°C. The solvent indicated between parentheses corresponds to the solvent Co used to carry out the measurement of optical rotation in degrees, and the letter "c”. ~~ : ~indicates the concentration of the solvent in g/100 ml. “NLA,” means that the Co optical rotation measurement is not applicable, | Sl co - the column "m/z” gives information on the molecular ion (M+H") or (M") observed by analysis of the products by mass spectrometry, either by LC-MS (liquid chromatography coupled to mass spectroscopy) carried out on an Agilent LC- : MSD Trap instrument in positive ESI mode, or by direct introduction by MS (mass spectroscopy) on an Autospec M (EBE) instrument using the DCI-NH, technique or using the electron impact technique on a Waters GCT instrument.
TABLE 1 , 3
R—N 4 2
R,
NU (0) 6 HN 0
Sp fo [8 nT ee [ei : HCI : 2 H Ph 2,6-(Cl),,3-CF3 (1:1) racemic
HCI Chiral 3 H Ph 2,6-(Cl),,3-CF3 (1:1) laevorotatory R
HCI
4 H Ph 2-Cl1,3-CF; racemic (1:1)
HCI
5 CsHs Ph 2-Cl,3-CF; racemic (1:1)
HCI Chiral
H Ph 2,6-(Cl),,3-CF3 (1:1) dextrorotatory S
HCI
7 CH, Ph 2-Cl,3-CF; racemic (1:1)
HCI
Bn Ph 2-CH;,3-CF; racemic (1:1)
HCI
Ph 2-Cl,3-CF; racemic (1:1)
HCI
10 H Ph 2-C1,3-C;Hs (1:1) racemic
TABLE 2 . . LCMS lowe | we ar
S| TOTS TERE FHA NeOR, 075200) |” HS [Tm wa ae (o [mwms| WA ae [oem ew
The compounds of the invention were subjected to a series of pharmacological tests which demonstrated their advantage as substances having therapeutic activities.
Study of glycine transport in SK-N-MC cells expressing the native human transporter giytt ['“Clglycine uptake is studied in SK-N-MC celis (human neuroepithelial cells) expressing the native human transporter glyt1, by measuring the radioactivity incorporated in the presence or absence of the test compound. The cells are cultured in a monolayer for 48 h in plates pretreated with 0.02% fibronectin. On the day of the experiment, the culture medium is removed and the cells are washed with a Krebs-
HEPES ([4-(2-hydroxyethyl)}piperazine]-1-ethanesulphonic acid) buffer at pH 7.4. Afier preincubation for 10 min at 37°C in the presence either of buffer (control batch), or of test compound at various concenirations, or of 10 mM glycine (determination of nonspecific uptake), 10 uM ["“Clglycine (specific activity 112 mCi/mmol) is then added. The incubation is continued for 10 min at 37°C, and the reaction is stopped by means of 2 washes with a Krebs-HEPES buffer at pH 7.4. The radioactivity incorporated by the cells is then estimated after adding 100 pl of liquid scintillant and stirring for 1 h. The counting is performed on a Microbeta Tri-lux™ counter. The effectiveness of the compound is determined by means of the ICs, which is the concentration of the compound which reduces by 50% the specific uptake of glycine, defined by the difference in radioactivity incorporated by the control batch and the batch which received the glycine at 10 mM.
The compounds of the invention, in this test, have an ICs, of the order of 0.001 to - 10 uM.
Table 3 indicates some examples of ICs, results for compounds according to the invention.
TABLE 3 [= eww]
The results of the tests carried out on the chiral compounds of the invention and the racemates thereof in general formula (I) show that they are inhibitors of the glyt1 glycine transporter present in the brain.
These results suggest that the compounds of the invention can be used for the treatment of cognitive andfor behavioural disorders associated with . neurodegenerative diseases, with dementia; for the .ireatment of psychoses, in particular of schizophrenia (deficient form and productive form), acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, obsessive-compulsive disorders; for the treatment of various forms of depression, including psychotic depression; for the treatment of bipolar disorders, manic disorders, mood disorders; for the treatment of disorders due to alcohol abuse or to alcohol withdrawal, sexual behaviour disorders, eating disorders, migraine; pain; sleep disorders. :
The compounds according to the invention can therefore be used for the preparation of medicaments, in particular medicaments which inhibit the glyt1 glycine transporter.
Thus, according to another of the aspects of the invention, a subject thereof is medicaments which comprise a compound of formula (I), or an addition salt of the latter with a pharmaceutically acceptable acid or else a hydrate or a solvate of the compound of formula (1).
A subject of the present invention is also pharmaceutical compositions containing an effective dose of at least one compound according to the invention, in the form of a pharmaceutically acceptable base, salt or solvate, and as a mixture, where appropriate, with suitable excipients.
Said excipients are chosen according to the pharmaceutical form and the method of administration desired.
The pharmaceutical compositions according to the invention may thus be intended for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal, rectal or intraocular administration. ~ 20 The unit administration forms may be, for example, tablets, gel capsules, granules, powders, oral or injectable solutions or suspensions, paiches or suppositories. For topical administration, ointments, lotions and collyria can be envisaged.
Said unit forms contain doses so as to allow a daily administration of 0.01 to 20 mg of active ingredient per kg of body weight, according to the galenical form. in order to prepare tablets, a pharmaceutical carrier which may be composed of diluents, for example lactose, microcrystalline cellulose or starch, and formulation additives such as binders (polyvinylpyrroiidone, hydroxypropylmethylceilulose, etc.), flow agents such as silica, and lubricants such as magnesium stearate, stearic acid, glyceryl fribehenate or sodium stearylfumarate, are added to the active ingredient, : which may or may not be micronized. Wetting agents or surfactants such as sodium lauryl sulphate can also be added.
The preparation techniques may be direct compression, dry granulation, wet granulation or the hot-melt process.
The tablets may be uncoated, sugar-coated, for example with sucrose, or coated with various polymers or other suitable materials. They can be designed so as to aliow rapid, delayed or sustained release of the active ingredient by virtue of polymer matrices or of specific polymers used in the coating.
In order to prepare gel capsules, the active ingredient is mixed with dry pharmaceutical carriers (simple mixing, dry or wet granulation, or the hot-melt process), or liquid or semi-solid pharmaceutical carriers.
The gel capsules may be hard or soft, and optionally film-coated, so as to have a rapid, sustained or delayed activity (for example, for an enteric form).
A composition in the form of a syrup or an elixir or for administration in the form of drops can contain the active ingredient together with a sweetener, preferably a calorie-free sweetener, methylparaben or propylparaben as antiseptic, a flavour enhancer and a colorant,
The water-dispersible powders and granules can contain the active ingredient as a mixture with dispersing agents or wetting agents, or dispersing agents, such as polyvinylpyrrolidone, as well as with sweeteners and flavour-correcting agents.
For rectal administration, recourse is had to suppositories prepared with binders which melt at the rectal temperature, for example cocoa butter or polyethylene glycols.
For parenteral administration, use is made of aqueous suspensions, isotonic saline solutions or injectable sterile solutions comprising pharmacologically compatible dispersing agents and/or weiting agents, for example propylene glycol or butylene glycol.
The active ingredient can also be formulated in the form of microcapsules, optionally with one or more supports or additives, or else with a polymer matrix or with a cyclodextrin (patches, sustained-reiease forms).
The topical compositions according to the invention comprise a medium compatible with the skin. They can be provided in particular in the form of aqueous, alcoholic or ~ agueous-alcoholic solutions, of gels, of water-in-oil or oil-in-water emulsions having the appearance of a cream or of a gel, of microemulsions or of aerosols, or else in the form of vesicular dispersions containing ionic and/or nonionic lipids. These galenical forms are prepared according to the usual methods in the fields under consideration.
By way of example, a unit administration form for a compound according to the invention in tablet form can comprise the following components: }
Compound according to the invention 50.0 mg
Mannitol 5 223.75 mg
Sodium croscarmellose 6.0 mg
Maize starch 15.0 mg
Hydroxypropylmethylcellulose 2.25 mg
Magnesium stearate 3.0mg ‘When given orally, the dose of active ingredient administered per day can reach 0.1 to mg/kg, in one or more intakes.
There may be particular cases where higher or lower dosages are appropriate; such dosages do not depart from the context of the invention. Depending on the usual practice, the dosage appropriate for each patient is determined by the physician according to the method of administration and the weight and response of said 20 patient.
According to another of its aspects, the present invention also relates to a method for treating ihe pathologies indicated above, which comprises the administration, to a patient, of an effective dose of a compound according fo the invention, or a pharmaceutically acceptable salt thereof.
Claims (23)
1. Compound of general formula (1) R— &" H : HN-° R, oo 5 in which: - R represents a hydrogen atom or a group chosen from the groups (C:-Cg)alkyl and (Cs-Cr)cycloalkyl, optionally substituted with one or more groups chosen, independently of one another, from halogen atoms and (Cs-Cr)oycloalkyl, (C,- Cslalkenyl, phenyl, (C;-Cglalkoxy and hydroxyl groups; the phenyl group being optionally substituted with one or more (C;-Cg)alkoxy groups; - R, represents a phenyl or naphthyl group, optionally substituted with one or more substituents chosen, independently of one another, from halogen atoms and (C;- Cealkyl, (Ci-Cs)alkoxy, halo-(C;-Cgalkyl, hydroxyl, halo-(C;-Cslalkoxy, (C-Cglalkyl- thio, (Ci-Cslalkyl-SO and (C4-Cg)alkyl-SO., groups; - R; represents one or more substituents chosen from a hydrogen atom, halogen atoms and halo-(C;-Cglalkyl, (Ci-Cslalkyl, (Cs-Cricycloalkyl, (Cs-C;)cycloalkyl(Cs- Cslalkyl, (Ci-Cglalkoxy, (Ci-Ceglalkyl-thio, (Ci-Cglalkyl-SO and (Ci-Cglalkyl-SO; : groups; in the form of a base or of an addition salt with an acid.
2. Compound of general formula (1) according to Claim 1, characterized in that R represents a hydrogen atom or a (C4-Cs)alkyl or benzyl group; Ryand R; being as defined in Claim 1, in the form of a base or of an addition salt with an acid.
3. Compound of general formula (I) according to Claim 1, characterized in that
Ry represents a phenyl group; R and R; being as defined in Claim 1, in the form of a base or of an addition salt with an acid.
4. Compound of general formula (lI) according to Claim 1, characterized in that R: represents one or more substituents chosen from a hydrogen atom, halogen atoms and halo~(C4-Cg)alkyl or (C4-Cs)alkyl groups; R and R, being as defined in Claim 1, in the form of a base or of an addition salt with an acid.
5. Compound of general formula (1) according to Claim 1, characterized in that R represents a hydrogen atom or a (C-Cg)alkyl or benzyl group; R, represents a phenyl group; Ry represents one or more substituents chosen from a hydrogen atom, halogen atoms and halo-(C;-Cg)alkyl or {C;-Cg)alkyl groups, in the form of a base or of an addition salt with an acid.
6. R represents a hydrogen atom or a methyl, ethyl or benzyi group; R represents a phenyl group; R; represents one or more substituents chosen from a hydrogen atom, a chlorine atom and methyl, ethyl or trifluoromethyl groups, in the form of a base or of an addition salt with an acid.
7. Compound according to Claim 1 or 2, characterized in that it is chosen from: eN-[(7-azabicyclo[2.2.1]hept-1-yi)phenylméthyl](2-methyl-3- trifluoromethyl)benzamide; eN-[(7-azabicyclo[2.2.1]hept-1-yl)phenylmethyl](2,6-dichioro-3- : trifluoromethyl )benzamide, and the hydrochloride thereof; o(-)-N-[(7-azabicyclo[2.2.1]hept-1-yi)phenylmethyl](2,6-dichioro-3- trifluoromethyl}benzamide, and the hydrochloride thereof; *N-[(7-azabicyclo[2.2.1]hept-1-yl)phenylmethyl](2-chioro-3-triflucromethyl)benzamide, and the hydrochloride thereof; 2-chloro-N-[(7-ethyl-7-azabicyclo[2.2.1]hept-1-yl)phenylmethyl}{ 3- trifluoromethyl)benzamide, and the hydrochloride thereof;
o(+)-N-[(7-azabicyclo[2.2.1]hept- 1-yl)phenylmethyl](2,6-dichloro-3- trifluoromethyl)benzamide, and the hydrochloride thereof; »2-chloro-N-[(7-methyl-7-azabicyclo[2.2.1]hept-1-yl)phenylmethyl]-3-trifluoromethyl- benzamide, and the hydrochloride thereof, eN-[(7-benzyl-7-azabicyclo[2.2.1]hept-1-yl)phenylmethyl}-(2-methyl-3-trifluoro- methyl)benzamide, and the hydrochloride thereof; oN-{(7-benzyl-7-azabicyclo[2.2.1]hept-1-yl)phenylmethyl](2-chloro-3- trifluoromethyl)benzamide, and the hydrochloride thereof; oN-[(7-azabicyclo[2.2.1]hept-1-yl)phenylmethyl](2-chloro-3-ethybenzamide, and the hydrochloride thereof.
8. Process for preparing a compound of general formula (I) according to Claim 1, : characterized in that a compound of generat formula {11} R—N &" (In) NH, in which R and R; are as defined according to Claim 1, reacts with a compound of general formula (Il) Y 0 (11) R, in which Y represents a leaving group or a halogen atom and R, is as defined according to Claim 1.
9. Compound of general formula (11) R—nN F< (ny NH, in which R and R; are as defined in Claim 1.
10. Medicament, characterized in thai it comprises a compound of formula (I)
according to any one of Claims 1 to 7, or an addition salt of this compound with a pharmaceutically acceptable acid.
11. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 7, or a pharmaceutically acceptable : salt of this compound, and also at least one pharmaceutically acceptable excipient.
12. Use of a compound of formula (I) according to any one of Claims 1 to 7, for the preparation of a medicament for the treatment of cognitive and/or behavioural disorders associated with neurodegenerative diseases; with dementia.
13. Use of a compound of formula (1) according to any one of Claims 1 to 7, for the preparation of a medicament for the treatment of psychoses, of schizophrenia (deficient form and productive form) and of acute or chronic extrapyramidal symptoms induced by neuroleptics.
14. Use of a compound of formula (1) according to any one of Claims 1 to 7, for the preparation of a medicament for the treatment of various forms of anxiety, panic attacks, phobias and obsessive-compulsive disorders.
15. Use of a compound of formula (I} according to any one of Claims 1 to 7, for the preparation of a medicament for the treatment of various forms of depression, including psychotic depression; for the treatment of bipolar disorders, manic disorders, mood disorders; for the treatment of disorders due to alcohol abuse or alcohol withdrawal, sexual behaviour disorders, eating disorders, and migraine.
16. Use of a compound of formula (I) according to any one of Claims 1 to 7, for the preparation of a medicament for the treatment of pain.
17. Use of a compound of formula (I) according to any one of Claims 1 to 7, for the preparation of a medicament for the {reatment of sleep disorders.
18. Compound according to any one of Claims 1 to 7, for the treatment of cognitive and/or behavioural disorders associated with neurodegenerative diseases; with dementia.
19. Compound according to any one of Claims 1 to 7, for the treatment of psychoses, of schizophrenia (deficient form and productive form) and of acute or chronic extrapyramidal symptoms induced by neuroleptics.
20. Compound according to any one of Claims 1 to 7, for the treatment of various forms of anxiety, panic attacks, phobias and obsessive-compulsive disorders.
21. Compound according to any one of Claims 1 to 7, for the treatment of various : 10 forms of depression, including psychotic depression; for the treatment of bipolar : disorders, manic disorders, mood disorders; for the treatment of disorders due to alcohol abuse or alcohol withdrawal, sexual behaviour disorders, eating disorders, : and migraine.
22. Compound according fo any one of Claims 1 fo 7, for the treatment of pain. -
23. Compound according to any one of Claims 1 to 7, for the treatment of sleep -disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0901809A FR2944284A1 (en) | 2009-04-14 | 2009-04-14 | N- (7-AZA-BICYCLO) 2.2.1! HEPT-1-YL) -LARYL-METHYL DERIVATIVES -BENZAMIDE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
PCT/FR2010/050711 WO2010119222A1 (en) | 2009-04-14 | 2010-04-13 | Derivatives of n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, preparation thereof, and therapeutic use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG175222A1 true SG175222A1 (en) | 2011-11-28 |
Family
ID=41228015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011075017A SG175222A1 (en) | 2009-04-14 | 2010-04-13 | Derivatives of n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, preparation thereof, and therapeutic use thereof |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2419431A1 (en) |
JP (1) | JP2012523448A (en) |
KR (1) | KR20120013378A (en) |
AR (1) | AR076276A1 (en) |
AU (1) | AU2010238409A1 (en) |
BR (1) | BRPI1015484A2 (en) |
CA (1) | CA2758367A1 (en) |
FR (1) | FR2944284A1 (en) |
IL (1) | IL215673A0 (en) |
MX (1) | MX2011010929A (en) |
SG (1) | SG175222A1 (en) |
TW (1) | TW201041581A (en) |
UY (1) | UY32561A (en) |
WO (1) | WO2010119222A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160045182A (en) | 2014-10-16 | 2016-04-27 | 현대자동차주식회사 | Gray cast iron for cylinder liner and method for manufacturing cylinder liner using the same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2842804B1 (en) * | 2002-07-29 | 2004-09-03 | Sanofi Synthelabo | N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
FR2861076B1 (en) * | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | N-HETEROCYCLYMETHYLBENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
WO2008065500A2 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
WO2009013535A1 (en) * | 2007-07-23 | 2009-01-29 | Astrazeneca Ab | 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor |
-
2009
- 2009-04-14 FR FR0901809A patent/FR2944284A1/en not_active Withdrawn
-
2010
- 2010-04-12 AR ARP100101220A patent/AR076276A1/en unknown
- 2010-04-13 AU AU2010238409A patent/AU2010238409A1/en not_active Abandoned
- 2010-04-13 BR BRPI1015484A patent/BRPI1015484A2/en not_active Application Discontinuation
- 2010-04-13 SG SG2011075017A patent/SG175222A1/en unknown
- 2010-04-13 KR KR1020117026894A patent/KR20120013378A/en not_active Application Discontinuation
- 2010-04-13 EP EP10723665A patent/EP2419431A1/en not_active Withdrawn
- 2010-04-13 TW TW099111503A patent/TW201041581A/en unknown
- 2010-04-13 JP JP2012505205A patent/JP2012523448A/en not_active Withdrawn
- 2010-04-13 WO PCT/FR2010/050711 patent/WO2010119222A1/en active Application Filing
- 2010-04-13 CA CA2758367A patent/CA2758367A1/en not_active Abandoned
- 2010-04-13 MX MX2011010929A patent/MX2011010929A/en not_active Application Discontinuation
- 2010-04-14 UY UY0001032561A patent/UY32561A/en not_active Application Discontinuation
-
2011
- 2011-10-10 IL IL215673A patent/IL215673A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI1015484A2 (en) | 2016-04-26 |
UY32561A (en) | 2010-11-30 |
MX2011010929A (en) | 2011-11-02 |
CA2758367A1 (en) | 2010-10-21 |
FR2944284A1 (en) | 2010-10-15 |
JP2012523448A (en) | 2012-10-04 |
TW201041581A (en) | 2010-12-01 |
EP2419431A1 (en) | 2012-02-22 |
KR20120013378A (en) | 2012-02-14 |
AU2010238409A1 (en) | 2011-11-03 |
AR076276A1 (en) | 2011-06-01 |
WO2010119222A1 (en) | 2010-10-21 |
IL215673A0 (en) | 2012-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4700007B2 (en) | N- [phenyl (pyrrolidin-2-yl) methyl] benzamide and N-[(azepan-2-yl) phenylmethyl] benzamide derivatives, their preparation and use in therapy | |
CA2684149C (en) | Metabolites of (thio)carbamoyl-cyclohexane derivatives | |
KR20060109432A (en) | Derivatives of n-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics | |
HU214578B (en) | Process for producing aryl-acetamides, pharmaceutical compositions comprising them and method for producing thereof | |
EP1615893B1 (en) | 2-azabicyclo¬3.3.1 nonane derivatives as opioid receptor antagonists | |
US20120029027A1 (en) | N-[(6-aza-bicyclo[3.2.1]oct-5-yl)-aryl-methyl]-heterobenzamide derivatives, preparation thereof, and therapeutic use of same | |
PL176051B1 (en) | Application of dimethylbezofuranes and dimethylbenzopyranes as antagonists of 5-ht 3 | |
SG175222A1 (en) | Derivatives of n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, preparation thereof, and therapeutic use thereof | |
WO2019236808A1 (en) | Salts of a oxazino[4,3-b]indazole derivative and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof | |
SG173607A1 (en) | N-[(6-azabicyclo[3.2.1]oct-1-yl)-aryl-methyl]-benzamide derivatives, preparation thereof, and therapeutic use thereof | |
US20120071536A1 (en) | N-[(2-azabicyclo[2.1.1]hex-1-yl)-aryl-methyl]-benzamide derivatives, preparation thereof, and therapeutic use thereof | |
EP1149079B1 (en) | Tetrahydro isoquino linealkanol derivatives and pharmaceutical compositions containing same | |
WO2023249871A1 (en) | Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment | |
JPS6046109B2 (en) | 1-(4-isopropylthiophenyl)-2-n-octanoylaminopropane derivative and method for producing the same | |
SG174434A1 (en) | Derivatives of n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, preparation thereof and application of same in therapeutics | |
MXPA06004266A (en) | Derivatives of n-[phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | |
FR2944283A1 (en) | New N-((2-aza-bicyclo(2.1.1)hex-1-yl)-aryl-methyl)-heterobenzamide derivatives are glycine-1 transporters useful for treating e.g. cognitive disorders, psychotic depression, bipolar disorder, manic disorders and mood disorders |